1. Linde R, Linde B. Lipids and risk assessment. Cardiol Rev 2001;9: 348-58.
2. Evans RW, Shaten BJ, Hempel JD, et al. Homocyst (e) ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
3. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
4. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease: meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
5. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-7.
6. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report Ateroskleroz Kardiovaskulyarnaya terapiya i profilaktika, 2008; 7(5) 15 Postupila 18/04-2008 of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: Recent Advances and Future Directions Clinical Chemistry 2003; 49: 1785-96.
7. MacLean JW, Tomlinson JE, Kuang WJ, et al. cDNA Sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987; 330: 132-7.
8. Foody JM, Milberg JA, Robinson K, et al. Homocysteine and lipoprotein (a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493-9.
9. Hopkins PN, Wu LL, Hunt SC, et al. Lipoprotein (a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997; 17: 2783- 92.
10. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst (e) inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
11. Bogaty P, Poirier P, Simard S, et al. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 2001; 103: 3062-8.
12. Harris M, Shammas NW, Jerin M. Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein (a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery. Prev Cardiol 2004; 7: 106-8.
13. Pokrovsky SN, Ezhov MV, Il`ina LN, et al. Association of lipoprotein (a) excess with early vein graft occlusions in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 126/4: 1071-5.
14. Vrentzos G, Papadakis JA, Malliaraki N, et al. Association of serum total homocysteine with the extent of ischemic heart disease in a Mediterranean cohort. Angiology 2004; 55(5): 517-24.
15. Ogawa M, Abe S, Saigo M, et al. Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age. Thromb Res 2003; 109(5-6): 253-8.
16. Herrmann W, Stanger O, Knapp JP, et al. Post-methionineload hyperhomocysteinemia and increased lipoprotein (a) are associated with renal metabolic dysfunction: a hypothesis. Metabolism 2002; 51(10): 1235-40.
17. Scanu AM, Fless GM. Lipoprotein (a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-15.
18. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants of lipoprotein (a) assembly: a study of wild-type and mutant apolipoprotein (a) phenotypes isolated from human and rhesus monkey lipoprotein (a) under mild reductive conditions. Biochemistry 1995; 34: 16483-92.
19. Lonn E, Yusuf S, Arnold MJ, et al. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354(15): 1567-77.
20. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
21. Seed M, O’Connor B, Perombelon N, et al. The effect of nicotinic acid and acipimox on lipoprotein (a) concentration and turnover. Atherosclerosis 1993; 101: 61-8.